[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"MBX Biosciences\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100054159","phase-3-a-study-to-investigate-canvuparatide-compared-with-placebo-in-adult-patients-with-hypoparathyroidism-100054159",false,"NCT07699471","A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Followed by an Open-Label Extension to Evaluate the Safety and Efficacy of Canvuparatide (MBX 2109) in Adult Patients With Hypoparathyroidism","Key Inclusion Criteria:\n\n1. Is an adult ≥18 years of age.\n2. Has a documented diagnosis of post-surgical, chronic HypoPT or genetic, idiopathic, or autoimmune HypoPT for at least 12 months prior to screening.\n3. Intact PTH level below the median value of the normal range\n4. Minimum requirement for a dose of calcitriol ≥0.5 μg\u002Fday, or alfacalcidol ≥1.0 μg\u002Fday and (elemental) calcium ≥1000 mg\u002Fday for at least 12 weeks prior to screening. In addition, the doses of calcitriol, or alfacalcidol, and calcium should be stable for at least 3 weeks prior to screening.\n5. Two (2) consecutive measurements of albumin-adjusted serum calcium at least 1 week apart within the range of 7.8 to 9.4 mg\u002FdL (1.95 to 2.35 mmol\u002FL).\n\nKey Exclusion Criteria:\n\n1. Has a known history of pseudohypoparathyroidism\n2. Clinically significant abnormal hematology, clinical chemistry, or coagulation.\n3. Any disease that might affect calcium metabolism or calcium-phosphate homeostasis or PTH levels other than HypoPT, such as active endogenous hyperthyroidism;\n4. Use of therapies affecting the calcium metabolism within 4 weeks prior to randomization\n5. PTH or PTH-related protein drugs such as PTH(1-84) and PTH(1-34) within 5 weeks prior to screening.","ALL","18 Years",{"count":19,"type":20},160,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The purpose of this study is to investigate the efficacy and safety of canvuparatide administered as a once-weekly (QW) treatment to adult study participants with hypoparathyroidism (HypoPT).",[26],"Hypoparathyroidism","RECRUITING","2026-07-07",{"date":30,"type":31},"2026-07-13","ACTUAL",{"date":33,"type":20},"2026-08",{"date":35,"type":20},"2029-08",{"name":37,"class":38},"MBX Biosciences","INDUSTRY",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100603914","phase-1-a-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-mbx-4291-in-adult-participants-with-obesity-100603914","NCT07142707","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity","A Randomized, Double-blind, Placebo-controlled First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of MBX 4291 in Adult Participants With Obesity","Inclusion Criteria:\n\n* Age of \\>18 to ≤65 years at the time of signing the informed consent.\n* Has a BMI of ≥30 to \\\u003C50 kg\u002Fm2 at screening and baseline.\n* Weight-stable, i.e., no more than ±5% change in body weight for at least 3 months prior to screening and between screening and baseline.\n\nExclusion Criteria:\n\n* History of, or currently active, significant illness or medical disorders that in the opinion of the investigator may preclude participants from participating in the study.\n* History of currently active pancreatitis, type I and type II diabetes.\n* Secondary causes of obesity, including but not limited to hypothalamic, monogenic, syndromic, or endocrine causes.\n* A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.","65 Years",{"count":48,"type":20},124,[50],"PHASE1","The purpose of this study is to evaluate the safety and tolerability of single and multiple subcutaneous (SC) doses of MBX 4291 in adults with obesity.",[53],"Obesity",[55,56,57,58],"Body Weight","Body Mass Index","Overweight","Nutrition Disorders","2026-06-08",{"date":61,"type":31},"2026-06-09",{"date":63,"type":31},"2025-09-03",{"date":65,"type":20},"2026-10-30",{"name":37,"class":38},4,""]